The U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.
THIS WEBPAGE IS HOSTED BY THE INTERNATIONAL MYELOMA FOUNDATION ("IMF") FOR A LOCAL MULTIPLE MYELOMA SUPPORT GROUP. THE CONTENT APPEARING ON THIS WEBPAGE IS NOT CONTROLLED OR PROVIDED BY IMF, AND IMF NEITHER WARRANTS NOR GUARANTEES THE ACCURACY OF SUCH CONTENT. THE FOREGOING NOTWITHSTANDING, THE CONTENT IS NOT A SUBSTITUTE FOR ADVICE AND SERVICE PROVIDED BY QUALIFIED AND LICENSED MEDICAL PROFESSIONALS, AND SHOULD NOT BE RELIED ON WITH RESPECT TO ANY HEALTH MATTERS. ANY HEALTH-RELATED INFORMATION FOUND HEREIN IS ONLY MADE AVAILABLE AS PART OF A GENERAL EDUCATIONAL SERVICE.